Carbon-ion radiotherapy in osteosarcoma of the mandible: a case report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Carbon-ion radiotherapy (CIRT) is on the rise as a treatment choice for malignant tumor. Compared to conventional radiotherapy, particle beams have different physical and biological properties. Particle beam provides a low entry dose, deposits most of the energy at the endpoint of the flight path, and forms an asymptotic dose peak (the “Bragg peak”). Compared to protons, carbon with its larger mass decreases beam scattering, resulting in a sharper dose distribution border. We report a 50-year-old male who underwent CIRT without surgical resection on osteosarcoma of the mandible. After CIRT, the patient’s pain was gone, and the malignant mass remained stable with accompanying necrosis. Nine months later, however, magnetic resonance imaging demonstrated progression of the left mandibular osteosarcoma with pulmonary metastases. After multidisciplinary discussion, concurrent chemoradiotherapy was conducted. While necrotic bone segments came out of the mandible during subsequent periodic outpatient visits, the tumor itself was stable. Thirty months after his first visit and diagnosis, the patient is waiting for chemotherapy. Although CIRT is superior in treating radioresistant hypoxic disease, CIRT is in its infancy, so care must be taken for its indications and complications.
Abstract
Carbon-ion radiotherapy (CIRT) is on the rise as a treatment choice for malignant tumor. Compared to conventional radiotherapy, particle beams have different physical and biological properties. Particle beam provides a low entry dose, deposits most of the energy at the endpoint of the flight path, and forms an asymptotic dose peak (the “Bragg peak”). Compared to protons, carbon with its larger mass decreases beam scattering, resulting in a sharper dose distribution border. We report a 50-year-old male who underwent CIRT without surgical resection on osteosarcoma of the mandible. After CIRT, the patient’s pain was gone, and the malignant mass remained stable with accompanying necrosis. Nine months later, however, magnetic resonance imaging demonstrated progression of the left mandibular osteosarcoma with pulmonary metastases. After multidisciplinary discussion, concurrent chemoradiotherapy was conducted. While necrotic bone segments came out of the mandible during subsequent periodic outpatient visits, the tumor itself was stable. Thirty months after his first visit and diagnosis, the patient is waiting for chemotherapy. Although CIRT is superior in treating radioresistant hypoxic disease, CIRT is in its infancy, so care must be taken for its indications and complications.
참고문헌 (20)
- Seungtaek Lim, "Cranofacial osteosarcoma: Single institutional experience in Korea", Asia-Pacific Journal of Clinical Oncology, 12(1), pp.e149~e153 (2016), Wiley[DOI]
- Erich M. Sturgis, "Sarcomas of the head and neck region", Current Opinion in Oncology, 15(3), pp.239~252 (2003), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Schwarz R, "Pediatric and adolescent osteosarcoma. Cancer treatment and research", pp.147~164 (2010), Springer
- 정혜인, "Osteosarcoma of the jaws in Koreans: analysis of 26 cases", 대한구강악안면외과학회지, 43(5), pp.312~317 (2017), 대한구강악안면외과학회
- Gennady N. Machak, "Neoadjuvant Chemotherapy and Local Radiotherapy for High-Grade Osteosarcoma of the Extremities", Mayo Clinic Proceedings, 78(2), pp.147~155 (2003), Elsevier BV[DOI]
- Geoff Delaney, "The role of radiotherapy in cancer treatment", Cancer, 104(6), pp.1129~1137 (2005), Wiley[DOI]
- Neville B, "Oral and maxillofacial pathology" (2015), Saunders
- Arvind Krishnamurthy, "Osteosarcomas of the Head and Neck Region: A Case Series with a Review of Literature", Journal of Maxillofacial and Oral Surgery, 17(1), pp.38~43 (2018), Springer Science and Business Media LLC[DOI]
- Raafat F. Makary, "Margin Analysis", Oral and Maxillofacial Surgery Clinics of North America, 29(3), pp.355~366 (2017), Elsevier BV[DOI]
- Yutaro Kimura, "Conventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report", Journal of Medical Case Reports, 11(1) (2017), Springer Science and Business Media LLC[DOI]
- Daniel K. Ebner, "The Emerging Role of Carbon-Ion Radiotherapy", Frontiers in Oncology, 6 (2016), Frontiers Media SA[DOI]
- Lin Kong, "Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I", III clinical trial, 2019, pp.39(1), 5~[DOI]
- Durante M, "Nuclear physics in particle therapy : a review", Rep Prog Phys, 79, pp.096702~ (2016)[DOI]
- O. Mohamad, "Clinical Indications for Carbon Ion Radiotherapy", Clinical Oncology, 30(5), pp.317~329 (2018), Elsevier BV[DOI]
- Claudia Blattmann, "Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma", BMC Cancer, 10(1) (2010), Springer Science and Business Media LLC[DOI]
- Osama Mohamad, "Evolution of Carbon Ion Radiotherapy at the National Institute of Radiological Sciences in Japan", Cancers, 10(3), pp.66~ (2018), MDPI AG[DOI]
- Matthew T Ballo, "Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma", International Journal of Radiation Oncology*Biology*Physics, 58(5), pp.1461~1467 (2004), Elsevier BV[DOI]
- Keiichi Jingu, "Carbon Ion Radiation Therapy Improves the Prognosis of Unresectable Adult Bone and Soft-Tissue Sarcoma of the Head and Neck", International Journal of Radiation Oncology*Biology*Physics, 82(5), pp.2125~2131 (2012), Elsevier BV[DOI]
- Kohyama K, "Salvage surgery and microsurgical reconstruction for recurrence of skull base osteosarcoma after carbon ion radiotherapy", Nagoya J Med Sci, 77, pp.667~673 (2015)
- Go Sasahara, "Effects of the dose-volume relationship on and risk factors for maxillary osteoradionecrosis after carbon ion radiotherapy", Radiation Oncology, 9(1) (2014), Springer Science and Business Media LLC[DOI]